A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma

Here, we report the results of a phase I/II, single-arm study (UMIN-CTR Clinical Trial Registry UMIN000002661) assessing the safety (primary endpoint) of G47∆, a triple-mutated oncolytic herpes simplex virus type 1, in Japanese adults with recurrent/progressive glioblastoma despite radiation and tem...

Descripción completa

Detalles Bibliográficos
Autores principales: Todo, Tomoki, Ino, Yasushi, Ohtsu, Hiroshi, Shibahara, Junji, Tanaka, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304402/
https://www.ncbi.nlm.nih.gov/pubmed/35864115
http://dx.doi.org/10.1038/s41467-022-31262-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304402/
https://www.ncbi.nlm.nih.gov/pubmed/35864115
http://dx.doi.org/10.1038/s41467-022-31262-y

Ejemplares similares